Company profile
Roche
Diversified pharma
RHHBY · OTC · Switzerland
Share price · RHHBY
$55.53+4.43 (+8.67%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(46 total)
46Total Assets
17Approved
15Phase 3 / Filed
14Phase 1–2 / Early
17Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Undisclosed / early pipeline · Thymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | PD-L1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Approved | VEGF-A · Undisclosed / early pipelineMonoclonal antibody | Non-Small Cell Lung Cancer | |
Diazepam (Valium)(Valium) | Approved | GABA-A receptorSmall molecule | Epilepsy |
| Approved | ROS1/NTRKSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | Angiopoietin-2 / VEGF-AMonoclonal antibody | Age-Related Macular Degeneration | |
| Approved | PI3K-alphaSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | CD20Monoclonal antibody | Multiple Sclerosis | |
Ocrevus Zunovo(Ocrevus Zunovo) | Approved | CD20Monoclonal antibody | Multiple Sclerosis |
Omalizumab(Xolair) | Approved | Undisclosed / early pipeline · IgEMonoclonal antibody | Asthma |
orlistat(Xenical / Alli) | Approved | Pancreatic/gastric lipaseSmall molecule | Obesity |
| Approved | RETSmall molecule | Non-Small Cell Lung Cancer | |
Ranibizumab(Lucentis) | Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
| Approved | CD20 · Undisclosed / early pipelineMonoclonal antibody | Rheumatoid Arthritis | |
| Approved | PD-L1Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.